Multicenter clinical trial of zinc acexamate in the prevention of nonsteroidal antiinflammatory drug induced gastroenteropathy. Spanish Study Group on NSAID Induced Gastroenteropathy Prevention.

What Was Tested

This randomized controlled trial looks at Aminocaproic Acid.

To assess in a multicenter double blind clinical trial the gastroenteroprotective effect of zinc acexamate (ZAC).

Who Took Part

According to the abstract, 276 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

276 patients with rheumatic disease and history of peptic ulcer or intolerance to nonsteroidal antiinflammatory drugs (NSAID), and requiring treatment with these drugs were included.

An initial normal endoscopy was needed for inclusion.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

The patients were allocated by chance, so the Aminocaproic Acid group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Aminocaproic Acid.

A placebo (an inactive look-alike) gave the Aminocaproic Acid group a baseline to be compared against.

More than one site took part, so the patients came from several places.

What Was Measured

PubMed files the paper under topics including Aminocaproates, Aminocaproic Acid, Anti-Inflammatory Agents, Non-Steroidal, Anti-Ulcer Agents, Endoscopy, Incidence and Peptic Ulcer.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Aminocaproic Acid in 276 patients.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1994 (The Journal of rheumatology), a journal based in Canada.

More context: all human trials.